Peripheral arterial tonometry for risk stratification in men with coronary artery disease

Clinical Cardiology

Volumn 33, Issue 2, 2010, Pages 94-98

  Heffernan, Kevin S ^a   Karas, Richard H ^a   Patvardhan, Eshan A ^a   Jafri, Haseeb ^a   Kuvin, Jeffrey T ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; HUMAN; HYPEREMIA; LOGISTIC REGRESSION ANALYSIS; MALE; PERIPHERAL ARTERIAL TONOMETRY; PREDICTION AND FORECASTING; PULSE WAVE; RISK ASSESSMENT; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARTERIES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FINGERS; HUMANS; HYPEREMIA; LOGISTIC MODELS; MALE; MANOMETRY; MICROCIRCULATION; MIDDLE AGED; PLETHYSMOGRAPHY; PREDICTIVE VALUE OF TESTS; PULSATILE FLOW; RISK ASSESSMENT; RISK FACTORS;

EID: 77649267839     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20705     Document Type: Article

References (37)

1. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007;100:n32-40.
2. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944-2948.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
4. Suessenbacher A, Frick M, Alber HF, et al. Association of improvement of brachial artery flow-mediated vasodilation with cardiovascular events. Vasc Med. 2006;11:239-244.
5. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009;53:323-330.
6. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146:168-174.
7. Kuvin JT, Mammen A, Mooney P, et al. Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med. 2007;12:13-16.
8. Dhindsa M, Sommerlad SM, Devan AE, et al. Interrelationships among noninvasive measures of postischemic macro- and microvascular reactivity. J Appl Physiol. 2008;105:427-432.
9. Nohria A, Gerhard-Herman M, Creager MA, et al. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol. 2006;101:545-548.
10. Yeo TW, Lampah DA, Gitawati R, et al. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparummalaria. J Exp Med. 2007;204:2693-2704.
11. Aversa A, Vitale C, Volterrani M, et al. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med. 2008;25:37-44.
12. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol. 2003;41:1761-1768.
13. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117:2467-2474.
14. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by peripheral arterial tonometry predicts cardiovascular events beyond the Framingham Risk Score. J Am Coll Cardiol. 2009;53:A457.
15. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44:2137-2141.
16. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framinghamstudy. Am Heart J. 2000;139:272-281.
17. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102:1K-34K.
18. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182.
19. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascularevents inmen andwomenwith elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
20. 2 as a cardiovascular risk marker. Am J Cardiol. 2008;101:41F-50F.
21. 2 : a riskmarker or a risk factor? Am J Cardiol. 2008;101:11F-22F.
22. 2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40:376-381.
23. 2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101:51F-57F.
24. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586-1593.
25. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903-1908.
26. 2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165:2479-2484.
27. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837-842.
28. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505-510.
29. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488.
30. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Postgrad Med J. 2008;84:368-371.
31. Clapp BR, Hirschfield GM, Storry C, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation. 2005;111:1530-1536.
32. Kals J, Kampus P, Kals M, et al. Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest. 2008: 1-8.
33. Liuba P, Aburawi EH, Pesonen E, et al. Residual adverse changes in arterial endothelial function and LDL oxidation after a mild systemic inflammation induced by influenza vaccination. Ann Med. 2007;39:392-399.
34. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart. 2006;92:441-444.
35. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation. 2002;105:2600-2604.
36. Vitale C, Cerquetani E, Wajngarten M, et al. In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy. Ital Heart J. 2003;4:627-632.
37. Kang SM, Chung N, Kim JY, et al. Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease. Echocardiography. 2002;19:661-667.